RENAL DAMAGE WITH MALIGNANT NEOPLASMS

The relationship between renal damage and malignant neoplasms is one of the most actual problems of the medicine of internal diseases. Very often, exactly availability of renal damage determines the forecast of cancer patients. The range of renal pathologies associated with tumors is unusually wide: from the mechanical effect of the tumor or metastases on the kidneys and/or the urinary tract and paraneoplastic manifestations in the form of nephritis or amyloidosis to nephropathies induced with drugs or tumor lysis, etc. Thrombotic complications that develop as a result of exposure to tumor effects, side effects of certain drugs or irradiation also play an important role in the development of the kidney damage. The most frequent variants of renal damage observed in the practice of medical internists (therapists, urologists, surgeons, etc.), as well as methods of diagnosis and treatment approaches are described in the article. Timely and successful prevention and treatment of tumor-associated nephropathies give hope for retaining renal functions, therefore, a higher life standard after completion of anti-tumor therapy. Even a shortterm episode of acute renal damage suffered by a cancer patient must be accompanied with relevant examination and treatment. In the case
of transformation of acute renal damage into the chronic kidney disease, such patients need systematic and weighted renoprotective therapy and correct dosing of nephrotoxic drugs.

1. Fried L.F., Katz R., Sarnak M.J. et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005;16(12):3728–35.

2. Manning E.C., Belenko M.I., Frauenhoffer E.E., Ahsan N. Acute renal failure secondary to solid tumor renal metastases: сase report and review of the literature. Am J Kidney Dis 1996;27(2):284–91.

3. Wagle D.G., Moore R.H., Murphy G.P. Secondary carcinomas of the kidney. J Urol 1975;114(1):30–2.

4. Hande K.R., Garrow G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94(2):133–9.

5. Ronco C., Inguaggiato P., Bellomo V. et al. Rasburicase therapy in acute hyperuricemia and renal dysfunction. Contrib Nephrol 2005;147:115–23.

6. Кондратьев В.Б., Мартынюк В.В., Ли Л.А. Метастазы в кости: осложненные формы, гиперкальциемия, синдром компрессии спинного мозга, медикаментозное лечение. Практическая онкология 2000;2(6):41–5. [Kondratiyev V.B., Martynyuk V.V., Li L.A. Bone metastases: complicated forms, hypercalcemia, spinal cord compression syndrome, medication therapy. Prakticheskaya onkologiya = Practical Oncology 2000;2(6):41–5. (In Russ.)].

7. Мuggia F.M. Overview of cancer-related hypercalcemia: epidemiology and etiology. Semin Oncol 1990;17(2 Suppl 5): 3–9.

8. Kanis J., Orourke N., McCloskey E. Consequences of neoplasia induced boneresorption and the use of clodronate (review). Int J Oncol 1994;5(4):713–31.

9. Markowitz G.S., Fine P.L., D’Agati V.D. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002:39(5): 1118–22.

10. Markowitz G.S., Fine P.L., Stack J.I. et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64(1):281–9.

11. Banerjee D., Asif A., Striker L. et al. Shortterm, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003;41(5):E18.

12. Smetana S., Michlin A., Rosenman E. et al. Pamidronate-induced nephrotoxic tubular necrosis – a case report. Clin Nephrol 2004;61(1):63–7.

13. Сомонова О.В. Тромботические осложнения и их профилактика у больных со злокачественными новообразованиями. Урология сегодня 2010;(5):12–3.

14. [Somonova O.V. Thrombotic complications and their prevention with patients with malignant neoplasms. Today's Urology 2010;(5):12–3. (In Russ.)].

15. Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 uppl):381S–453S.

16. Метелева Н.А., Козловская Н.Л., Спесивцев В.Н., Глазкова Е.К. Лучевая терапия как причина нарушения функциипочек и артериальной гипертензии при опухолях урогенитальной локализации. Нефрология и диализ 2008;10(3–4):234–9. [Meteleva N.A., Kozlovskaya N.L., Spesivtsev V.N., Glazkova E.K. Radiation therapy as a cause of renal dysfunction and hypertension with tumors of the urogenital localization. Nephrology and Dyalysis 2008;10(3–4):234–9. (In Russ.)].

17. Bacсhetta J., Juillard L., Cochat P., Droz J.P. Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol 2009;70(1):39–58.

18. Ronco P.M. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999;56(1):355–77.

19. Козловская Л.В., Туганбекова С.К., Сейсембеков Т.З. и др. Паранеопластическое поражение почек при солидных опухолях. Нефрология и диализ 2002;4(2): 76–81. [Kozlovskaya L.V., Tuganbeckova S.K., Seisembeckov T.Z. et al. Paraneoplastic renal damage with solid tumors. Nephrology and Dyalysis 2002;4(2):76–81. (In Russ.)].

20. Merlini G., Pozzi C. Mechanisms of renal damage in plasma cell dyscrasias: an overview. Contrib Nephrol 2007;153:66–86.

21. Lien Y.H., Lai L.W. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol 2011;7(2): 85–95.